The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Rise In Market Size Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market During The Forecast Period?
The market size for b-cell maturation antigen (bcma) targeted therapies has experienced significant expansion in recent years. This market is projected to increase from $15.09 billion in 2025 to $18.75 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 24.3%. The growth witnessed in the historical period can be attributed to an improved understanding of bcma biology, the increasing prevalence of multiple myeloma, early successful clinical trials of bcma-targeted therapies, the expansion of hematology oncology centers, and rising investment in immuno-oncology research.
The b-cell maturation antigen (bcma) targeted therapies market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $44.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 24.0%. This anticipated growth during the forecast period is driven by factors such as the increasing approvals of next-generation bcma therapies, a rising demand for off-the-shelf immunotherapies, the expansion of combination treatment strategies, a growing emphasis on durable remission outcomes, and the increasing application of AI-driven patient stratification. Key trends for this period encompass the increasing adoption of CAR-T cell therapies, the rising development of bispecific antibody platforms, the growing utilization of BCMA-targeted ADCs, the expansion of personalized immunotherapy regimens, and an enhanced focus on care for relapsed and refractory myeloma.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
What Influential Factors Are Boosting The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Demand?
The increasing occurrence of multiple myeloma is projected to fuel the expansion of the b-cell maturation antigen (BCMA) targeted therapies market moving forward. Multiple myeloma is a cancer type primarily impacting plasma cells, which are vital components of the immune system responsible for antibody production. Several elements contribute to the rising prevalence of multiple myeloma, including an aging global populace, enhanced diagnostic capabilities, and disparities in healthcare availability. B-cell maturation antigen (BCMA) targeted therapies play a critical role in treating multiple myeloma by specifically targeting and eradicating malignant plasma cells that express BCMA, thereby presenting a hopeful method for more potent and focused treatment. For instance, in August 2024, data from the American Cancer Society, a US-based professional body, indicated that approximately 35,780 new multiple myeloma cases were diagnosed in the United States during 2024, comprising 19,520 cases in men and 16,260 in women. Furthermore, around 12,540 deaths are expected, with 7,020 among men and 5,520 among women. Consequently, the growing incidence of multiple myeloma is a significant catalyst for growth within the b-cell maturation antigen (BCMA) targeted therapies market.
How Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Structured Across Different Market Segments?
The b-cell maturation antigen (bcma) targeted therapies market covered in this report is segmented –
1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies
2) By Indication Type: Multiple Myeloma, Plasma Cell Leukemia
3) By End User: Hospitals, Specialty Clinics
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
What Trends Are Affecting The Growth Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
Leading companies in the B-cell maturation antigen (BCMA) targeted therapies market are concentrating on developing innovative treatments, such as CAR-T cell therapy, to improve the effectiveness and precision of targeting cancer cells. This CAR-T cell therapy represents a type of immunotherapy that involves modifying a patient’s T cells to express chimeric antigen receptors (CARs) for the purpose of targeting and eliminating cancer cells. For example, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy designed for treating adult patients with relapsed or refractory multiple myeloma who have received a minimum of one prior line of therapy and are resistant to lenalidomide.
Who Are The Firms Contributing To The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Ecosystem?
Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences
Access The Complete B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report:
Which Region Contributes The Most To The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in the b-cell maturation antigen (bcma) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=20718&type=smp
Browse Through More Reports Similar to the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2026, By The Business Research Company
Malignant Melanoma Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report
Oral Cancer Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report
Neuroendocrine Tumor Treatment Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model